Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Chief Commercial Officer | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,042 |
Reported balance
After 2025-03-03 transaction · row 1
1 source rowRow 1 · 2025-03-03 · Sale · Disposed 2,407 · Balance 36,042 F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,407 | $76.43 | $183,967.01 |
DisclosureSEC source: 0000950170-25-033706 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,042 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:07 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 26,499 | $0.00 Strike: $77.12 | $0.00 |
DisclosureSEC source: 0000950170-25-028040 · ownership.xml · derivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,499 Underlying: Common Stock · 26,499 shares Expires 2035-02-24 F2 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following February 24, 2025 until the option is fully vested on February 24, 2029, subject to continued service. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:07 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantCommon Stock | 17,606 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028040 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,449 F1 · shares: Consists of 17,606 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 16:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-25-004192 · ownership.xml · derivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,167 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 16:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,083 | $80.05 | $86,694.15 |
DisclosureSEC source: 0000950170-25-004192 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $80.00 to $80.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 16:29 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-25-004192 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 18:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,084 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-133392 · ownership.xml · derivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 1,084 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 18:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,084 | $86.40 | $93,657.60 |
DisclosureSEC source: 0000950170-24-133392 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $86.21 to $86.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 18:00 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,084 | $13.28 | $14,395.52 |
DisclosureSEC source: 0000950170-24-133392 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-126397 · ownership.xml · derivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 1,458 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,458 | $90.04 | $131,278.32 |
DisclosureSEC source: 0000950170-24-126397 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.00 to $90.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,458 | $38.46 | $56,074.68 |
DisclosureSEC source: 0000950170-24-126397 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-121525 · ownership.xml · derivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,334 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,083 | $82.64 | $89,499.12 |
DisclosureSEC source: 0000950170-24-121525 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.55 to $82.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-24-121525 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · derivative · entry 15 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,417 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · derivative · entry 14 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,098 Underlying: Common Stock · 417 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · derivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,292 Underlying: Common Stock · 1,458 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 134 | $154.86 | $20,751.24 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $154.785 to $154.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 20 | $153.75 | $3,075.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,977 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 80 | $152.28 | $12,182.40 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,997 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 80 | $151.20 | $12,096.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,077 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 318 | $150.38 | $47,820.84 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,157 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $150.07 to $150.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 523 | $149.59 | $78,235.57 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,475 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $149.06 to $150.005, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 80 | $147.98 | $11,838.40 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,998 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 900 | $146.90 | $132,210.00 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,078 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $146.555 to $147.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 823 | $146.15 | $120,281.45 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,978 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $145.54 to $146.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 417 | $66.10 | $27,563.70 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,458 | $38.46 | $56,074.68 |
DisclosureSEC source: 0000950170-24-112394 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,084 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · derivative · entry 14 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 1,084 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F11 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · derivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,515 Underlying: Common Stock · 417 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F10 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,459 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · derivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 1,459 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $165.87 | $16,587.00 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 32 | $164.68 | $5,269.76 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,943 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $164.60 to $164.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 80 | $163.09 | $13,047.20 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,975 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $162.55 to $163.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 700 | $161.54 | $113,078.00 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,055 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $161.21 to $161.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 396 | $160.67 | $63,625.32 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,755 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $160.19 to $161.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 132 | $159.02 | $20,990.64 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,151 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $158.85 to $159.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 921 | $158.09 | $145,600.89 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,283 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $157.83 to $158.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 599 | $157.27 | $94,204.73 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,204 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $156.82 to $157.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,084 | $13.28 | $14,395.52 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 417 | $66.10 | $27,563.70 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,459 | $38.46 | $56,113.14 |
DisclosureSEC source: 0000950170-24-104046 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · derivative · entry 20 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,584 Underlying: Common Stock · 1,083 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F17 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · derivative · entry 19 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,932 Underlying: Common Stock · 417 shares Expires 2033-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F16 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 20, 2027. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · derivative · entry 18 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,209 Underlying: Common Stock · 1,458 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F15 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 24, 2025. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 14 | $166.00 | $2,324.00 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 17 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 84 | $164.98 | $13,858.32 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 16 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,857 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F14 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $164.80 to $165.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:08 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 32 | $163.65 | $5,236.80 |
DisclosureSEC source: 0000950170-24-091017 · ownership.xml · nonDerivative · entry 15 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,941 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F13 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $163.28 to $164.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.